Senores Pharmaceuticals Ltd
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
- Market Cap ₹ 3,280 Cr.
- Current Price ₹ 712
- High / Low ₹ 751 / 435
- Stock P/E 889
- Book Value ₹ 154
- Dividend Yield 0.00 %
- ROCE 2.15 %
- ROE 0.84 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 4.63 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 0.99% over last 3 years.
- Earnings include an other income of Rs.22.0 Cr.
- Company has high debtors of 243 days.
- Working capital days have increased from -372 days to 105 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE IPO BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
7.91 | 13.54 | 12.38 | 34.01 | 38.54 | |
6.89 | 12.38 | 14.16 | 34.07 | 45.82 | |
Operating Profit | 1.02 | 1.16 | -1.78 | -0.06 | -7.28 |
OPM % | 12.90% | 8.57% | -14.38% | -0.18% | -18.89% |
0.15 | 0.94 | 6.79 | 6.84 | 21.99 | |
Interest | 0.20 | 0.56 | 2.14 | 2.71 | 6.52 |
Depreciation | 0.57 | 0.71 | 0.93 | 2.04 | 3.08 |
Profit before tax | 0.40 | 0.83 | 1.94 | 2.03 | 5.11 |
Tax % | -110.00% | 18.07% | 38.14% | 60.10% | 27.79% |
0.84 | 0.68 | 1.20 | 0.81 | 3.69 | |
EPS in Rs | 2.21 | 0.69 | 1.22 | 0.27 | 0.80 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 42% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 76% |
TTM: | 356% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 1% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 3.80 | 8.74 | 9.82 | 30.51 | 46.05 |
Reserves | 5.67 | 24.95 | 29.11 | 137.61 | 661.92 |
3.71 | 14.75 | 60.66 | 100.69 | 102.74 | |
1.78 | 6.73 | 12.13 | 17.05 | 23.38 | |
Total Liabilities | 14.96 | 55.17 | 111.72 | 285.86 | 834.09 |
1.69 | 1.59 | 7.77 | 24.09 | 54.59 | |
CWIP | 2.71 | 3.17 | 11.33 | 18.47 | 34.01 |
Investments | 1.45 | 11.69 | 8.23 | 81.58 | 104.38 |
9.11 | 38.72 | 84.39 | 161.72 | 641.11 | |
Total Assets | 14.96 | 55.17 | 111.72 | 285.86 | 834.09 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
-2.87 | -24.06 | -43.41 | -19.26 | -20.40 | |
-4.37 | -10.05 | -5.23 | -57.07 | -162.94 | |
8.50 | 33.88 | 47.08 | 86.68 | 532.62 | |
Net Cash Flow | 1.25 | -0.23 | -1.57 | 10.35 | 349.28 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 10.61 | 225.63 | 463.77 | 236.21 | 243.30 |
Inventory Days | 31.10 | 132.65 | 194.00 | 120.51 | 299.04 |
Days Payable | 11.89 | 269.30 | 272.97 | 310.08 | 452.37 |
Cash Conversion Cycle | 29.82 | 88.98 | 384.80 | 46.65 | 89.98 |
Working Capital Days | 196.57 | 101.63 | -566.07 | -656.06 | 105.31 |
ROCE % | 4.51% | 5.51% | 2.57% | 2.15% |
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 2d
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
2d - AGM Sep 18, 2025: adopted FY ended Mar 31, 2025 financials; reappointments; MD/WTD remuneration revised; secretarial auditor appointed.
-
Intimation Under Regulation 30(6) Of SEBI (LODR) Regulations, 2015.
2d - Invested USD 1,999,968 through rights issue in wholly-owned SPI; turnover USD11.41M FY25.
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
12 Sep - Completed acquisition of remaining 540 Havix shares; total 8,454 shares now acquired.
- Reg. 34 (1) Annual Report. 5 Sep
Concalls
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
May 2025TranscriptNotesPPT
-
Jan 2025Transcript PPT REC
Business Overview:[1]
SPL is global research driven pharmaceutical company which develops and manufactures
pharmaceutical products for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Company develops and manufactures specialty, underpenetrated and complex pharmaceutical products. It also manufactures criticalcare injectables and APIs